Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Reg. & Quality Off. | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,572 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 53,572 F1: Restricted stock unit award that vests on 03/31/2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verve Therapeutics, Inc.
Report date July 25, 2025 · Filed July 28, 2025
Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-25 · Disposition to issuer · Disposed 267,541 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-25 · Disposition to issuer · Disposed 42,200 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the
F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2021 Filed Feb 26, 2021 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,036 | $217.57 | $225,402.52 |
DisclosureSEC source: 0001209191-21-014752 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,432 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,000 | $211.75 | $423,500.00 |
DisclosureSEC source: 0001209191-21-012360 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,468 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,230 | $214.16 | $263,416.80 |
DisclosureSEC source: 0001209191-21-010129 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,468 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 13,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,698 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,746 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,552 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9 | $288.38 | $2,595.42 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,738 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $288.38 (range $288.20 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 33 | $287.61 | $9,491.13 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,747 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $287.61 (range $287.04 to $287.99). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $286.12 | $5,722.40 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,780 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $286.12 (range $285.79 to $286.44). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $284.30 | $2,843.00 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 21 | $281.23 | $5,905.83 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $281.23 (range $280.73 to $281.62). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17 | $279.93 | $4,758.81 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,831 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $279.93 (range $279.68 to $280.53). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $276.35 | $2,763.50 |
DisclosureSEC source: 0001209191-20-030494 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,848 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 407 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · derivative · entry 10 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,854 Underlying: Common Stock · 407 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 559 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · derivative · entry 9 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Underlying: Common Stock · 559 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30 | $275.30 | $8,259.00 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 8 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,738 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 330 | $274.13 | $90,462.90 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,768 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $274.13 (range $273.75 to $274.73). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 210 | $273.15 | $57,361.50 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $273.15 (range $272.73 to $273.50). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 217 | $272.09 | $59,043.53 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,308 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $272.09 (range $271.73 to $272.54). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 136 | $270.19 | $36,745.84 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,525 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $270.19 (range $269.71 to $270.61). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 43 | $268.80 | $11,558.40 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,661 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $268.80 (range $268.65 to $269.12). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 407 | $155.57 | $63,316.99 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 559 | $187.53 | $104,829.27 |
DisclosureSEC source: 0001209191-20-027906 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $237.81 | $57,074.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,738 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $237.81 (range $237.24 to $238.18). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $235.39 | $37,662.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,978 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $235.39 (range $235.33 to $235.44). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $234.43 | $56,263.20 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,138 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $234.43 (range $234.14 to $234.89). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $232.43 | $18,594.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $231.82 | $37,091.20 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,458 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.82 (range $231.27 to $232.37). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 416 | $229.57 | $95,501.12 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,618 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.57 (range $229.15 to $229.91). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,036 | $239.23 | $247,842.28 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,034 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 145 | $245.75 | $35,633.75 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,070 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.54 to $245.85). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 286 | $244.99 | $70,067.14 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,215 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.52 to $245.30). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $243.78 | $39,004.80 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,501 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.78 (range $243.42 to $244.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 528 | $242.78 | $128,187.84 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,661 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.38 to $243.31). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $241.82 | $38,691.20 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,189 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.82 (range $241.33 to $242.18). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 597 | $241.50 | $144,175.50 |
DisclosureSEC source: 0001209191-20-010560 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,349 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 408 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · derivative · entry 10 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,261 Underlying: Common Stock · 408 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 559 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · derivative · entry 9 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,704 Underlying: Common Stock · 559 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 66 | $242.47 | $16,003.02 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 8 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,946 F3 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 90 | $240.70 | $21,663.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,012 F3 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F5 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $240.70 (range $240.47 to $241.04). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $239.68 | $57,523.20 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,102 F3 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F5 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $239.68 (range $239.25 to $240.13). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 571 | $238.77 | $136,337.67 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,342 F3 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.20 to $239.14). F5 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 408 | $155.57 | $63,472.56 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 559 | $187.53 | $104,829.27 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,946 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,752 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,675 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-003055 · doc4.xml · derivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,263 Underlying: Common Stock · 1,675 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,675 | $227.53 | $381,112.75 |
DisclosureSEC source: 0001209191-20-003055 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,675 | $187.53 | $314,112.75 |
DisclosureSEC source: 0001209191-20-003055 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5 | $205.95 | $1,029.75 |
DisclosureSEC source: 0001209191-19-057152 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.